Peak Pharma Commercial Partners, a United States-based investment fund that deals with the acquisition and growth of branded, generic and over-the-counter pharmaceutical products, has established and started operations of Resilia Pharmaceuticals Inc, it was reported on Monday.
Resilia's product range includes Ecoza (econazole nitrate) topical foam, Recedo topical gel, Neosalus foam and Neocera, the ceramide version of Neosalus.
Presently, these products are approved and marketed in the United States and the company says that they have been prescribed and used safely and effectively by thousands of patients.
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US